321 related articles for article (PubMed ID: 32213152)
21. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-κb pathways in non-pregnant and pregnant populations.
Celik O; Celik N; Aydin S; Baysal B; Aydin S; Saglam A; Gursu Y; Dalkilic S; Ulas M; Ozcil MD; Tayyar AT; Cengiz F; Ugur K; Akkoc RF; Ersahin AA
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):221-229. PubMed ID: 32538775
[TBL] [Abstract][Full Text] [Related]
22. Does Ibuprofen Worsen COVID-19?
Moore N; Carleton B; Blin P; Bosco-Levy P; Droz C
Drug Saf; 2020 Jul; 43(7):611-614. PubMed ID: 32529474
[No Abstract] [Full Text] [Related]
23. Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
Perišić O
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32967116
[TBL] [Abstract][Full Text] [Related]
24. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.
Ngwa W; Kumar R; Thompson D; Lyerly W; Moore R; Reid TE; Lowe H; Toyang N
Molecules; 2020 Jun; 25(11):. PubMed ID: 32545268
[TBL] [Abstract][Full Text] [Related]
25. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
[TBL] [Abstract][Full Text] [Related]
26. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Vasanthakumar N
Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
[No Abstract] [Full Text] [Related]
27. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Riva L; Yuan S; Yin X; Martin-Sancho L; Matsunaga N; Pache L; Burgstaller-Muehlbacher S; De Jesus PD; Teriete P; Hull MV; Chang MW; Chan JF; Cao J; Poon VK; Herbert KM; Cheng K; Nguyen TH; Rubanov A; Pu Y; Nguyen C; Choi A; Rathnasinghe R; Schotsaert M; Miorin L; Dejosez M; Zwaka TP; Sit KY; Martinez-Sobrido L; Liu WC; White KM; Chapman ME; Lendy EK; Glynne RJ; Albrecht R; Ruppin E; Mesecar AD; Johnson JR; Benner C; Sun R; Schultz PG; Su AI; García-Sastre A; Chatterjee AK; Yuen KY; Chanda SK
Nature; 2020 Oct; 586(7827):113-119. PubMed ID: 32707573
[TBL] [Abstract][Full Text] [Related]
28. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
Pizzorno A; Padey B; Dubois J; Julien T; Traversier A; Dulière V; Brun P; Lina B; Rosa-Calatrava M; Terrier O
Antiviral Res; 2020 Sep; 181():104878. PubMed ID: 32679055
[TBL] [Abstract][Full Text] [Related]
29. Are children less susceptible to COVID-19?
Lee PI; Hu YL; Chen PY; Huang YC; Hsueh PR
J Microbiol Immunol Infect; 2020 Jun; 53(3):371-372. PubMed ID: 32147409
[No Abstract] [Full Text] [Related]
30. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
Thalha AMM; Lee YY; Besari A; Omar SFS
J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289
[No Abstract] [Full Text] [Related]
31. [Chloroquine as a possible treatment for COVID-19].
Coumou J; de Vries PJ
Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999
[TBL] [Abstract][Full Text] [Related]
32. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
[No Abstract] [Full Text] [Related]
33. A Review of Remdesivir for COVID-19: Data to Date.
Mehta M; Shyh GI
Cardiol Rev; 2020; 28(6):332-334. PubMed ID: 32773440
[TBL] [Abstract][Full Text] [Related]
34. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
[TBL] [Abstract][Full Text] [Related]
35. Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Zhou H; Fang Y; Xu T; Ni WJ; Shen AZ; Meng XM
Br J Pharmacol; 2020 Jul; 177(14):3147-3161. PubMed ID: 32368792
[TBL] [Abstract][Full Text] [Related]
36. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Wu L; O'Kane AM; Peng H; Bi Y; Motriuk-Smith D; Ren J
Biochem Pharmacol; 2020 Aug; 178():114114. PubMed ID: 32579957
[TBL] [Abstract][Full Text] [Related]
38. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):585-586. PubMed ID: 32439198
[TBL] [Abstract][Full Text] [Related]
39. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
[No Abstract] [Full Text] [Related]
40. Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity.
Drew ED; Janes RW
BMC Mol Cell Biol; 2020 Jul; 21(1):49. PubMed ID: 32611313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
